As of November 6, 2026, Lixte Biotechnology Holdings, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 1, 2026 to July 2, 2026, naming 2 appointments. The latest filing names John Travaglini, appointed (Form 8-K, July 2, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Lixte Biotechnology Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Lixte Biotechnology Holdings, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-01 to 2026-07-02. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Lixte Biotechnology Holdings, Inc. files it.
Also on the record for Lixte Biotechnology Holdings, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 28, 2026 | Stake report, Schedule 13G, by North York Ltd | 9.8% of the class | 5%+ stakes | Source |
| July 31, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.02% of the class | 5%+ stakes | Source |
| June 9, 2026 | Stake report, Schedule 13G, by Strategic EP, LLC | 5.1% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Lixte Biotechnology Holdings, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Lixte Biotechnology Holdings, Inc. and the records around it.
Lixte Biotechnology Holdings, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- North York Ltd also filed stake reports on 1 other company: Earlyworks Co., Ltd. (Nov 2025)
- Strategic EP, LLC also filed stake reports on 6 other companies: Earlyworks Co., Ltd. (Aug 2026), GREENLAND MINES LTD (Mar 2026), GridAI Technologies Corp. (Jan 2026)
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
Watch Lixte Biotechnology Holdings, Inc.
Get an email when Lixte Biotechnology Holdings, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Lixte Biotechnology Holdings, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Lixte Biotechnology Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lixte Biotechnology Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-02 | In | 8-K, 2026-07-02 | |||
| 2026-06-01 | In | Director | 2026-05-29 | 8-K, 2026-06-01 |
Who leads Lixte Biotechnology Holdings, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Stuart D. Porter, appointed, effective 2026-05-29 (filed 2026-06-01).
New leaders reset buying decisions — get the Full Report on Lixte Biotechnology Holdings, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Lixte Biotechnology Holdings, Inc., with the record behind each one.
Find candidates like Director at Lixte Biotechnology Holdings, Inc.Every change, in the filing's words
Appointed: John Travaglini
On July 1, 2026, the Board appointed John Travaglini to the Board, effective immediately, with a term expiring at the Company's 2026 annual meeting of stockholders.
- The Company has not yet determined the committee(s) on which Mr. Travaglini will serve.
- In connection with his appointment, Mr. Travaglini will participate in the Company's standard non-employee director compensation program, as described under "Director Compensation" in the Company's proxy statement for its 2025 annual meeting of stockholders filed with the Securities and Exchange Commission on October 27, 2025.
Appointed: Stuart D. Porter, Director, effective 2026-05-29
On May 29, 2026, the Board of Directors (the "Board") of Lixte Biotechnology Holdings, Inc., (the "Company"), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company's 2026 Annual Meeting of Stockholders.
- Mr. Porter, age 60, has over 29 years of senior investment experience, including as a Founder and Managing Partner of Denham Capital, where he currently serves as the Chief Executive Officer and Chief Investment Officer.
- Mr. Porter also serves on Denham Capital's Investment Committee and Valuation Committee.
- Prior to founding Denham Capital in 2004, Mr. Porter was a founding partner of Sowood Capital Management LP and, prior thereto, was employed as a Vice President and Portfolio Manager at Harvard Management Company, Inc., where he focused on public and private transactions in the energy and commodities sectors.
- Mr. Porter previously worked for Bacon Investments and at J. Aron, a division of Goldman Sachs.
- While at J. Aron, he worked on the Goldman Sachs Commodity Index desk.
- Prior to joining J. Aron, Mr. Porter was a self-employed trader at the Chicago Board of Trade and was employed by Cargill Incorporated in Minnetonka, Minnesota in the Financial Markets Division.
- Mr. Porter received a Bachelor of Arts from the University of Michigan and a Master of Business Administration degree from the University of Chicago Booth School of Business.
Tools for this story
Each opens in a new tab, filled in for Lixte Biotechnology Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.